您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Avasimibe
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Avasimibe
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Avasimibe图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
50mg电议
200mg电议

产品介绍
Avasimibe (CI-1011; PD-148515) 是一种具有口服活性的酰基辅酶 A-胆固醇酰基转移酶 (ACAT; 也称为 SOAT)) 抑制剂,对 ACAT1 和 ACAT2 的 IC50 分别为 24 和 9.2 μM。 Avasimibe可用于前列腺癌的研究。

Cell lines

HepG2 cells; rat hepatocytes; THP-1 cells

Preparation method

The solubility of this compound in DMSO is >25.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.2 μM-10 μM; 24 h

Applications

In THP-1 cells, avasimibe (0-0.2 μM) did not reduce intracellular cholesteryl ester content in a sequential incubation system. Incubations with avasimibe (0-0.2 μM) during the process of lipid loading (simultaneous incubation with avasimibe and acetyl-LDL) caused a concentration-dependent reduction in cellular cholesteryl ester content, which reached 70% at 0.2 μM. Incubation with avasimibe (10 nM - 10 μM) for 24 h caused a significant dose-dependent reduction in apo B 100 secretion from HepG2 cells. Overnight incubation of HepG2 cells with 10 μM avasimibe suppressed apo B synthesis, as well as the synthesis of other hepa-to-specific proteins. Avasimibe (3 μM) caused a 2.9-fold increase in total bile acid synthesis in rat hepatocytes.

Animal models

Rats, Mice

Dosage form

Oral; 1, 10, or 30 mg/kg/day; 2 weeks

Application

In mice, treatment with avasimibe significantly reduced the number of lesions containing accumulations of free cholesterol. In cholesterol-fed rats treated with multiple oral doses of the compound, avasimibe significantly reduced plasma total cholesterol and increased HDL-cholesterol. Avasimibe (0.01% in the diet for 1 week) reduced plasma cholesterol levels in rats fed a high fat-high cholesterol diet, supplemented or not with 0.5% cholate, by 52 to 71%. Treatment with avasimibe (3–30 mg/kg/day) for 8–10 weeks lowered plasma total cholesterol, VLDL-cholesterol, LDL-cholesterol, and triglyceride levels.In chow-fed rats, avasimibe (3–30 mg/kg) reduced plasma cholesterol levels by 44 to 66%.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

Avasimibe is an orally bioavailable inhibitor of the acyl coenzyme A: cholesterol acyltransferase (ACAT) with IC50 value of 60nM [1].

Avasimibe is developed from a strategy to design ACAT inhibitors with improved bioavailability. It also has solution stability at acidic pH. In the in vitro assay, the IC50 value is dependent on the concentration of microsomes, the amount of membrane available for adsorption as well as the presence of BSA. The treatment of avasimibe during the process of lipid loading causes a concentration-dependent reduction in cellular cholesteryl ester content. This reduction is not accompanied by the accumulation of intracellular free cholesterol, indicating a better safety profile for avasimibe than other ACAT inhibitors. Avasimibe can also reduce the synthesis and secretion of Apo B 100 (a component of VLDL) in HepG2 cells. In addition, avasimibe can increase the total bile acid synthesis in rat hepatocytes at the concentration of 3μM [1].

Apart from the antiatherosclerotic efficacy, avasimibe is also found to take participate in the modulation of APP trafficking. It can delay and reduce the maturation of APP, limiting the availability of APP holoprotein for Aβ-generatiion [2].

References:
[1] Llaverías G, Laguna JC, Alegret M. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). 2003 Spring;21(1):33-50.
[2] Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J. 2009 Nov;23(11):3819-28.